Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Levitz

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2023
A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AMLDavid Levitz, Yogen Saunthararajah, Kateryna Fedorov, et al.
Blood Cancer Journal|August 21, 2025
Assessing the performance of the Iceland screens, treats, or prevents multiple myeloma (iStopMM) model in a multicultural Bronx cohort: implications for monoclonal gammopathy of undetermined significance risk stratificationRajvi Gor, Jeevan Shivakumar, Pallavi Surana, et al.
Cancer Cell|February 27, 2022
Impact of COVID-19 on case fatality rate of patients with cancer during the Omicron waveMatthew Lee, Ryann Quinn, Kith Pradhan, et al.
JMIR Cancer|January 6, 2026
Financial Toxicity of Hematologic Malignancy Therapies, Including Cellular Therapy and Its Impact on Access to Care: Prospective Pilot StudyLemchukwu Amaeshi, Lauren Laufer, Kateryna Fedorov, et al.
Haematologica|July 17, 2025
Metronomic low-dose regimen of decitabine and venetoclax is safe and reduces monocyte burden in chronic myelomonocytic leukemiaBradley Rockwell, Mendel Goldfinger, Ioannis Mantzaris, et al.
Cancer Cell|November 28, 2021
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancerLauren C Shapiro, Astha Thakkar, Sean T Campbell, et al.
Blood|September 24, 2024
A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohortMendel Goldfinger, Ioannis Mantzaris, Aditi Shastri, et al.
Haematologica|April 2, 2026
Treatment of <i>TP53</i>-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclaxMendel Goldfinger, Ioannis Mantzaris, Aditi Shastri, et al.
Therapeutic Advances in Neurological Disorders|November 11, 2024
The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort studyDavid Levitz, Yi Chao Foong, Paul Sanfilippo, et al.
Journal of Neurology|June 27, 2024
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemicAnoushka P Lal, Yi Chao Foong, Paul G Sanfilippo, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2023
A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AMLDavid Levitz, Yogen Saunthararajah, Kateryna Fedorov, et al.
Blood Cancer Journal|August 21, 2025
Assessing the performance of the Iceland screens, treats, or prevents multiple myeloma (iStopMM) model in a multicultural Bronx cohort: implications for monoclonal gammopathy of undetermined significance risk stratificationRajvi Gor, Jeevan Shivakumar, Pallavi Surana, et al.
Cancer Cell|February 27, 2022
Impact of COVID-19 on case fatality rate of patients with cancer during the Omicron waveMatthew Lee, Ryann Quinn, Kith Pradhan, et al.
JMIR Cancer|January 6, 2026
Financial Toxicity of Hematologic Malignancy Therapies, Including Cellular Therapy and Its Impact on Access to Care: Prospective Pilot StudyLemchukwu Amaeshi, Lauren Laufer, Kateryna Fedorov, et al.
Haematologica|July 17, 2025
Metronomic low-dose regimen of decitabine and venetoclax is safe and reduces monocyte burden in chronic myelomonocytic leukemiaBradley Rockwell, Mendel Goldfinger, Ioannis Mantzaris, et al.
Cancer Cell|November 28, 2021
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancerLauren C Shapiro, Astha Thakkar, Sean T Campbell, et al.
Blood|September 24, 2024
A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohortMendel Goldfinger, Ioannis Mantzaris, Aditi Shastri, et al.
Haematologica|April 2, 2026
Treatment of <i>TP53</i>-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclaxMendel Goldfinger, Ioannis Mantzaris, Aditi Shastri, et al.
Therapeutic Advances in Neurological Disorders|November 11, 2024
The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort studyDavid Levitz, Yi Chao Foong, Paul Sanfilippo, et al.
Journal of Neurology|June 27, 2024
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemicAnoushka P Lal, Yi Chao Foong, Paul G Sanfilippo, et al.
Pageof 2